Theoretical study for the inhibition ability of some bioactive imidazole derivatives against the Middle-East respiratory syndrome corona virus (MERS-Co)
Clicks: 371
ID: 86390
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
371 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #2 of 3 articles by views in zanco journal of pure and applied sciences
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The Severe Acute Respiratory Syndrome (SARS) is a serious viral life-threatening and mortal respiratory illness caused by SARS-CoV. SARS-CoV plays an essential role in the viral replication cycle. It is considered a potential target for SARS inhibitor development. A series of twenty eight bioactive imidazole compounds as possible SARS-CoV inhibitors were designed and evaluated using computational calculations. Possible binding interaction modes were proposed by molecular docking studies. Among all studied compounds, compounds 5, 15 and 22 showed most potent inhibitory activity against SARS-CoV. These results indicated that these inhibitors could be potentially developed into anti-SARS drugs.
| Reference Key |
abdallah2019theoreticalzanco
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Abdallah, Hassan; |
| Journal | zanco journal of pure and applied sciences |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.